Source comparison
Oral Formulation Claims Versus Published Data
The disconnect between marketing claims and peer-reviewed evidence is nowhere sharper than with oral BPC-157 products. Most suppliers claim 'enhanced bioavailability' through enteric coating, liposomal delivery, or cyclodextrin complexation. But none of these
This comparison does not assign a generated winner or score.
- The disconnect between marketing claims and peer-reviewed evidence is nowhere sharper than with oral BPC-157 products. Most suppliers claim 'enhanced bioavailability' through enteric coating, liposomal delivery, or cyclodextrin complexation. But none of these methods have been validated in published human pharmacokinetic studies for BPC-157 specifically.
- Enteric coating delays peptide release until the capsule reaches the small intestine (pH 5.5–6.0), but this is precisely where pancreatic protease activity peaks. Trypsin and chymotrypsin cleave peptide bonds between specific amino acids. And BPC-157's sequence contains multiple cleavage sites. The coating protects the peptide from gastric acid but delivers it directly into the enzymatic environment most likely to degrade it.
- Liposomal encapsulation wraps the peptide in a phospholipid bilayer, theoretically protecting it from enzymatic contact until the liposome fuses with intestinal cells. In vitro data shows this improves stability compared to unprotected peptides, but the absolute bioavailability remains low. Most studies on liposomal peptide delivery report systemic absorption in the 8–12% range for small peptides, and BPC-157's specific uptake has not been characterized in human trials.
- Cyclodextrin complexation uses a ring-shaped sugar molecule to encapsulate the peptide, shielding it from degradation. This method works well for certain hydrophobic drugs but peptides are hydrophilic. The interaction is weaker, and the protective effect diminishes rapidly once the complex reaches the intestinal lumen.
- Here's the blunt reality: if oral BPC-157 worked as effectively as subcutaneous injection, the published research would reflect that. It doesn't. The Zagreb studies. Which represent the bulk of peer-reviewed BPC-157 data. Use gastric instillation for local GI effects and subcutaneous injection for systemic effects. They don't use oral capsules. That's not an oversight. It's a signal about what the researchers know works.
- Our experience across hundreds of peptide research protocols shows the same outcome: injectable formulations produce measurable tissue-level effects; oral capsules produce expensive urine. That pattern holds across BPC-157, thymosin beta-4 fragments, and most other tissue-repair peptides.